Postoperative Pain Treatment Market Size in the 7MM was ~USD 3000 Million in 2023 and It is projected by 2034, estimates DelveInsight

DelveInsight's "Postoperative Pain Drugs Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of postoperative pain, historical and forecasted epidemiology, as well as the postoperative pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Postoperative Pain Market Share @ Postoperative Pain Market Outlook- https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Postoperative Pain Market Report
• The total number of surgical procedures in the US was around 50 million in 2023.
• In 2023, there were approximately 67 million total incident cases of postoperative pain in the 7MM. These cases are expected to increase by 2034 driven by the increase in the number of traffic accidents, relative trauma injuries, and area unit needs for pain management following surgeries.
• The US contributed to the largest number of incident cases of postoperative pain ~60.41% in the 7MM in 2023. Whereas, EU4 and the UK and Japan accounted for around 21.14% and 18.43% of the total incident cases in the 7MM, respectively, in 2023.
• According to DelveInsight, in 2023, it is estimated that the severity-specific incident cases of postoperative pain in France were nearly 1.2 million, 1.5 million, and 0.8 million in mild, moderate, and severe cases and is expected to increase by 2034 with increased incidence cases of postoperative pain.
• In 2023, it is estimated that the severity-specific incident cases of postoperative pain in Germany were approximately 1.4 million, 1.7 million, and 1 million in mild, moderate, and severe cases and is expected to increase during the forecast period (2024-2034).
• The total number of surgical procedures in Japan was found to be nearly 15 million cases, out of which nearly 3 million, 5.5 million, and 3 million were of mild, moderate, and severe severity-specific incident cases of postoperative pain in 2023. These cases are expected to increase during the forecast period with the increased occurrence of the aging population in Japan which will contribute to a higher incidence of chronic conditions and comorbidities among surgical patients.
• The leading Postoperative Pain Companies such as Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others.
• Promising Postoperative Pain Pipeline Therapies such as N1539, Intranasal Dexmedetomidine, CA-008 (vocacapsaicin), AYX1 Injection 660 mg / 6 mL and others.

Stay ahead in the Postoperative Pain Therapeutics Market with DelveInsight's Strategic Report @ Postoperative Pain Market Outlook- https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postoperative Pain Epidemiology Segmentation in the 7MM
• Total number of Postoperative Pain surgical procedures
• Total number of Postoperative Pain incident cases
• Postoperative Pain Severity-specific incident cases

Download the report to understand which factors are driving Postoperative Pain Epidemiology Trends @ Postoperative Pain Prevalence- https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postoperative Pain Marketed Drugs
• DEXTENZA (dexamethasone): Ocular Therapeutix
DEXTENZA is dexamethasone delivered via hydrogel technology. It is a corticosteroid indicated for treating ocular inflammation and pain following ophthalmic surgery and for treating ocular itching associated with allergic conjunctivitis. The Ocular Therapeutix product, DEXTENZA, is only approved in the US, where it received approval in December 2018 for treating ocular pain following ophthalmic surgery. However, later in June 2019, the US FDA approved the supplemental new drug application for DEXTENZA to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication.

• ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) contains bupivacaine, a local amide anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and is indicated in adults for soft tissue or periarticular instillation to produce post-surgical analgesia for up to 72 h after a bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. It is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72h of postoperative pain relief via a single needle-free application.

Postoperative Pain Emerging Drugs

• OCS-01: Oculis
Oculis is developing OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5% mg/mL), a novel formulation of dexamethasone using Oculis proprietary Solubilizing Nanoparticle (SNP) technology. OCS-01 has completed a Phase II trial in inflammation and pain following cataract surgery (SKYGGN trial), with 153 patients providing the first POC of a once-daily topical steroid. A long-acting topical. OCS-01 has also completed another Phase II trial in DME. Following the completion of both Phase II trials, an end-of-phase II meeting was conducted with the FDA, and as per the company, the product candidate is now moving into Phase III in both indications.

• Opiranserin (VVZ-149) Injections: Vivozon
Opiranserin (VVZ-149) for injection, developed by Vivozon, represents a groundbreaking non-narcotic analgesic being developed to address postoperative pain. It is a non-opioid and non-NSAID analgesic candidate and is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A). Positioned as a primary treatment option in the global market, VVZ-149 aims to supplant opioid analgesics by offering an efficient and safe alternative for pain management. To tackle opioid misuse and abuse, VVZ-149 is being assessed in Phase III clinical trials in both Korea and the US.

To learn more about Postoperative Pain treatment guidelines, visit @ Postoperative Pain Treatment Market Landscape- https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postoperative Pain Treatment Market
The current postoperative pain treatment market consists of different approaches classified into pharmacologic and non-pharmacological therapies. The pharmacological therapies include analgesics that are further segregated into opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, etc. Acute pain is also managed by the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids. Further, non-pharmacological therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM). All these involve the concept known as multimodal analgesia.

Postoperative Pain Market Outlook
Efficient pain management is critical for patients undergoing surgery, with its physiological benefits increasingly recognized as a key postoperative quality measure. Postoperative pain management seeks to alleviate discomfort with minimal side effects, yet evidence indicates that less than half of surgical patients achieve satisfactory pain relief. Despite the growing awareness of the value of multimodal pain management plans, opioid monotherapy remains the foundation of post-surgical pain therapy. Opioids delivered by patient-controlled analgesia support systemic analgesia for treating moderate-to-severe postoperative pain.

Learn more about the FDA-approved drugs for Postoperative Pain @ Drugs for Postoperative Pain Treatment- https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Postoperative Pain Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Postoperative Pain Companies- Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others.
• Postoperative Pain Pipeline Therapies- N1539, Intranasal Dexmedetomidine, CA-008 (vocacapsaicin), AYX1 Injection 660 mg / 6 mL and others.
• Postoperative Pain Therapeutic Assessment: Postoperative Pain Current marketed and Postoperative Pain emerging therapies
• Postoperative Pain Market Dynamics: Postoperative Pain market drivers and Postoperative Pain market barriers
• Postoperative Pain Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Postoperative Pain Unmet Needs, KOL's views, Analyst's views, Postoperative Pain Market Access and Reimbursement

Get a Free sample for the Postoperative Pain Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/postoperative-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Postoperative Pain Market Report Introduction
2. Executive Summary for Postoperative Pain
3. SWOT analysis of Postoperative Pain
4. Postoperative Pain Patient Share (%) Overview at a Glance
5. Postoperative Pain Market Overview at a Glance
6. Postoperative Pain Disease Background and Overview
7. Postoperative Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Postoperative Pain
9. Postoperative Pain Current Treatment and Medical Practices
10. Postoperative Pain Unmet Needs
11. Postoperative Pain Emerging Therapies
12. Postoperative Pain Market Outlook
13. Country-Wise Postoperative Pain Market Analysis (2020-2034)
14. Postoperative Pain Market Access and Reimbursement of Therapies
15. Postoperative Pain Market Drivers
16. Postoperative Pain Market Barriers
17. Postoperative Pain Appendix
18. Postoperative Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.